|Table of Contents|

Study on the role of Anlotinib in cervical cancer HeLa/DDP cells and the mechanism of reversing Cisplatin resistance

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 21
Page:
3927-3932
Research Field:
Publishing date:

Info

Title:
Study on the role of Anlotinib in cervical cancer HeLa/DDP cells and the mechanism of reversing Cisplatin resistance
Author(s):
WANG Huanhuan; MA Junwei; GAO Cancan; ZHAO Jingjing; ZHAO Hong
Department of Oncology,Affiliated Hospital of Yan'an University,Shaanxi Yan'an 716000,China.
Keywords:
cervical cancer; Anlotinib; P-gp; Cisplatin resistance
PACS:
R737.33
DOI:
10.3969/j.issn.1672-4992.2023.21.005
Abstract:
Objective:To investigate the effects of Anlotinib on the proliferation and apoptosis of cervical cancer HeLa/DDP cells and its mechanism of reversing Cisplatin resistance.Methods:HeLa/DDP cells were treated with different concentrations of Cisplatin and Anlotinib,and the proliferation ability of cells was detected by CCK-8 method.Apoptosis was detected by flow cytometry and the difference of P-gp expression level was detected by Western Blot.Results:Cisplatin inhibited the proliferation of HeLa/DDP cells in a dose-and time-dependent manner.Anlotinib inhibited the proliferation of HeLa/DDP cells in a concentration-dependent manner.Anlotinib and Anlotinib combined with Cisplatin inhibited the proliferation of HeLa/DDP cells(P<0.05).Flow cytometry results revealed an increased apoptosis rate in both the Anlotinib group and the Anlotinib combined with Cisplatin group(P<0.05).Anlotinib combined with Cisplatin significantly inhibited cell proliferation and induced apoptosis.Western Blot suggested that P-gp protein expression was upregulated in the Anlotinib combined with Cisplatin group compared with the control group and the Cisplatin group and the Anlotinib monotherapy group(P>0.05).Conclusion:Anlotinib inhibits proliferation and induces apoptosis in cervical cancer HeLa/DDP.Anlotinib combined with Cisplatin inhibits cell proliferation and induces apoptosis more significantly.Anlotinib increases the sensitivity of Cisplatin-resistant strains of cervical cancer HeLa/DDP to Cisplatin and reverses drug resistance,but does not mediate the down-regulation of resistance-associated protein P-gp expression.

References:

［1］ 刘宗超,李哲轩,张阳,等.2020全球癌症统计报告解读［J］.肿瘤综合治疗电子杂志,2021,7(02):1-14. LIU ZC,LI ZX,ZHANG Y,et al.Interpretation of the 2020 global cancer statistics report［J］.Electronic Journal of Integrative Oncology,2021,7(02):1-14.
［2］ KOH WJ,ABU-RUSTUR NR,BEA S,et al.Cervical cancer,version 3.2019,NCCN clinical practice guidelines in oncology ［J］.Journal of the National Comprehensive Cancer Network,2019,17(1):64-84.
［3］ BHATTACHARJEE R,DEY T,KUMAR L,et al.Cellular landscaping of Cisplatin resistance in cervical cancer ［J］.Biomed Pharmacother,2022,153:113345.
［4］ ZHU X,ZHU H,LUO H,et al.Molecular mechanisms of Cisplatin resistance in cervical cancer ［J］.Drug Design,Development and Therapy,2016,10:1885-1895.
［5］ VERGOTE I,RAY-COQUARD I,LORUSSO D,et al.Investigational drugs for recurrent or primary advanced metastatic cervical cancer:what is in the clinical development pipeline ［J］.Expert Opinion on Investigational Drugs,2023,32(3):201-211.
［6］ 谭顺梓,黄益玲,黄利鸣.宫颈癌的耐药机制［J］.生命的化学,2020,40(01):64-69. TAN SZ,HUANG YL,HUANG LM.Mechanisms of drug resistance in cervical cancer［J］.Chemistry of Life,2020,40(01):64-69.
［7］ HUANG J,ECKER GF.A structure-based view on ABC-transporter linked to multidrug resistance ［J］.Molecules(Basel,Switzerland),2023,28(2):495.
［8］ WANG JQ,WU ZX,YANG Y,et al.ATP-binding cassette(ABC) transporters in cancer:A review of recent updates ［J］.J Evid Based Med,2021,14(3):232-256.
［9］ AMAWI H,SIM HM,TIWARI AK,et al.ABC transporter-mediated multidrug-resistant cancer ［J］.Advances in Experimental Medicine and Biology,2019,1141:549-580.
［10］ SYED YY.Anlotinib:first global approval ［J］.Drugs,2018,78(10):1057-1062.
［11］ GAO Y,LIU P,SHI R.Anlotinib as a molecular targeted therapy for tumors ［J］.Oncol Lett,2020,20(2):1001-1014.
［12］ JI Y,LI X,QI Y,et al.Anlotinib exerts inhibitory effects against Cisplatin-resistant ovarian cancer in vitro and in vivo ［J］.Molecules(Basel,Switzerland),2022,27(24):8873.
［13］ QIN T,LIU Z,WANG J,et al.Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling ［J］.Cancer Biology & Medicine,2020,17(3):753-767.
［14］ 潘国友,郭慧,戚元刚,等.安罗替尼单药靶向治疗子宫颈癌肺转移1例 ［J］.中华妇产科杂志,2022,57(05):386-388. PAN GY,GUO H,QI YG,et al.A case of lung metastasis from cervical cancer treated with Anlotinib single-agent targeting ［J］.Chinese Journal of Obstetrics and Gynecology,2022,57(05):386-388.
［15］ YANG H,SUN S,MEI Z,et al.A retrospective cohort study evaluates clinical value of Anlotinib in persistent,metastatic,or recurrent cervical cancer after failure of first-line therapy ［J］.Drug Des Devel Ther,2021,15:4665-4674.
［16］ ZHU J,SONG C,ZHENG Z,et al.Anlotinib in Chinese patients with recurrent advanced cervical cancer:a prospective single-arm,open-label phase II trial ［J］.Frontiers in Oncology,2021,11:2234-2943.
［17］ 殷爱军,李鹏,宋坤,等.安罗替尼在妇科肿瘤治疗中的现状及研究进展 ［J］.现代妇产科进展，2022,31(05):384-388. YIN AJ,LI P,SONG K,et al.Current status and research progress of Anlotinib in gynecologic oncology treatment ［J］.Modern Advances in Obstetrics and Gynecology,2022,31(05):384-388.
［18］ BOUSSIOS S,SERAJ E,ZARKAVELIS G,et al.Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens:Where do we stand? A literature review ［J］.Critical Reviews in Oncology/Hematology,2016,108:164-174.
［19］ GHOUSH S.Cisplatin:The first metal based anticancer drug ［J］.Bioorganic Chemistry,2019,88:102925.
［20］毛万丽,李杰慧,冉立.宫颈癌顺铂耐药研究进展［J］.现代肿瘤医学,2021,29(16):2927-2932. MAO WL,LI JH,RAN L.Research progress on Cisplatin resistance in cervical cancer［J］.Modern Oncology,2021,29(16):2927-2932.
［21］ WANG G,SUN M,JIANG Y,et al.Anlotinib,a novel small molecular tyrosine kinase inhibitor,suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma ［J］.International Journal of Cancer,2019,145(4):979-993.
［22］ YANG Q,NI L,IMANI S,et al.Anlotinib suppresses colorectal cancer proliferation and angiogenesis via inhibition of AKT/ERK signaling cascade ［J］.Cancer Management and Research,2020,12:4937-4948.
［23］ 陈彦民,邹明雷,李丽,等.安罗替尼通过上调miR-33b抑制PI3K/AKT信号通路来抑制HeLa增殖、迁移侵袭的作用机制 ［J］.实用癌症杂志,2022,37(05):706-711. CHEN YM,ZOU ML,LI L,et al.Mechanism of action of Anlotinib to inhibit HeLa proliferation,migration and invasion by upregulating miR-33b to inhibit PI3K/AKT signaling pathway［J］.Journal of Practical Cancer,2022,37(05):706-711.
［24］ LAN W,ZHAO J,CHEN W,et al.Anlotinib overcomes multiple drug resistant colorectal cancer cells via inactivating PI3K/AKT pathway ［J］.Anti-Cancer Agents in Medicinal Chemistry,2021,21(15):1987-1995.
［25］ ZHU Y,WANG X,CHEN Z,et al.Anlotinib suppressed ovarian cancer progression via inducing G2/M phase arrest and apoptosis ［J］.Journal of Clinical Medicine,2022,12(1):162.
［26］ DENG Z,LIAO W,WEI W,et al.Anlotinib as a promising inhibitor on tumor growth of oral squamous cell carcinoma through cell apoptosis and mitotic catastrophe ［J］.Cancer Cell International,2021,21(1):37.
［27］ HE C,WU T,HAO Y.Anlotinib induces hepatocellular carcinoma apoptosis and inhibits proliferation via Erk and Akt pathway ［J］.Biochemical and Biophysical Research Communications,2018,503(4):3093-3099.
［28］ 陈芬,彭瑞宇,孟佳,等.正常宫颈、CIN、宫颈鳞癌中P-gp、MRP1、Survivin的相关表达及对新辅助化疗作用的研究 ［J］.医学理论与实践,2020,33(10):1571-1574. CHEN F,PENG RY,MENG J,et al.Correlated expression of P-gp,MRP1,Survivin in normal cervix,CIN,and squamous cervical carcinoma and its effect on neoadjuvant chemotherapy ［J］.Medical Theory and Practice,2020,33(10):1571-1574.
［29］ XIAO J,ZHOU J,LIANG L,et al.Sensitivity of ASPP and P-gp to neoadjuvant chemotherapy combined with gene therapy in locally advanced cervical cancer ［J］.Journal of BUON,2019,24(3):967-974.
［30］ SAKAEDA T,NAKAMURA T,HIRAI M,et al.MDR1 up-regulated by apoptotic stimuli suppresses apoptotic signaling ［J］.Pharmaceutical Research,2002,19(9):1323-1329.
［31］ MI YJ,LIANG YJ,HUANG HB,et al.Apatinib(YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters ［J］.Cancer Research,2010,70(20):7981-7991.
［32］ KITAZAKI T,OKA M,NAKAMURA Y,et al.Gefitinib,an EGFR tyrosine kinase inhibitor,directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells ［J］.Lung Cancer,2005,49(3):337-343.
［33］ FENG SQ,WANG GJ,ZHANG JW,et al.Combined treatment with apatinib and docetaxel in A549 xenograft mice and its cellular pharmacokinetic basis ［J］.Acta Pharmacologica Sinica,2018,39(10):1670-1680.
［34］ WANG G,CAO L,JIANG Y,et al.Anlotinib reverses multidrug resistance(MDR) in osteosarcoma by inhibiting P-Glycoprotein(PGP1) fun ction in vitro and in vivo ［J］.Front Pharmacol,2021,12:798837.

Memo

Memo:
北京康盟慈善基金会医学科研发展基金项目（编号：TB212028）
Last Update: 2023-09-28